Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.44 |
| ▸ | ATP4B | P51164 | 3/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.44 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.44 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.44 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.44 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.44 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.44 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.44 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 9/20 | 0.41 |
| ▸ | NOS1 | P29475 | 8/20 | 0.41 |
| ▸ | NOS3 | P29474 | 6/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CBFB | Q13951 | 3/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11005003 | 0.99 | ATP4A (0.43) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9526670 | 0.92 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9526743 | 0.92 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9530813 | 0.91 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9379675 | 0.91 | ATP4A (0.54) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL3693636 | 0.90 | ATP4A (0.54) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9527842 | 0.89 | NOS2 (0.40) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6873292 | 0.89 | NOS2 (0.40) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9686941 | 0.89 | ATP4A (0.48) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9527724 | 0.88 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0134400-B1 | FLUOROALKOXYSUBSTITUTED PYRIDYLMETHYLTHIO-(OR SULFINYL-)BENZIMIDAZOLES HAVING A SECRETOLYTIC ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1993-03-24 | — | — | EP | claimed |
| US-4555518-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1985-11-26 | — | — | US | claimed |
| EP-0134400-A2 | Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-03-20 | — | — | EP | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0134400-B1 | FLUOROALKOXYSUBSTITUTED PYRIDYLMETHYLTHIO-(OR SULFINYL-)BENZIMIDAZOLES HAVING A SECRETOLYTIC ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1993-03-24 | — | — | EP | disclosed |
| US-4555518-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1985-11-26 | — | — | US | disclosed |
| EP-0134400-A2 | Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | ATP4A 1/4885ATP4B 8/4885ATP1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.